The BNT162b2 (BioNTech/Pfizer) vaccine had 95% efficacy against COVID-19 ≥7 days after the 2nd dose.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

58 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Guillain-Barré syndrome and COVID-19 vaccination: a systematic review and meta-analysis.Journal of neurology · 2024
   Pooled it
2. SARS-CoV-2 vaccines elicit differential Fc effector functions.iScience · 2025
   Article
3. Exploring the Relation Between Health Literacy, Infodemic, and Acceptance of COVID-19 Vaccination in Iran: A Cross-Sectional Study.Health literacy research and practice · 2024
   Article
4. Influence of AAV vector tropism on long-term expression and Fc-γ receptor binding of an antibody targeting SARS-CoV-2.Communications biology · 2024
   Article
5. Ischemic and Inflammatory Ocular Adverse Events Following Different Types of Vaccination for COVID-19 and Their Incidence Analysis.Korean journal of ophthalmology : KJO · 2024
   Article
6. Thermally Robust Solvent-Free Liquid Polyplexes for Heat-Shock Protection and Long-Term Room Temperature Storage of Therapeutic Nucleic Acids.Biomacromolecules · 2024
   Article
7. mRNA-LNP prime boost evolves precursors toward VRC01-like broadly neutralizing antibodies in preclinical humanized mouse models.Science immunology · 2024
   Article
8. Global Disparities in Access to Vaccine Clinical Trials: A Review of the Literature.Vaccines · 2024
   Review
9. Influence of epidemiological and clinical factors in the reactogenicity to Comirnaty® vaccine in health care workers of a Spanish university teaching hospital (COVIVAC study).Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2023
   Article
10. An mRNA-based T-cell-inducing antigen strengthens COVID-19 vaccine against SARS-CoV-2 variants.Nature communications · 2023
    Article
11. mRNA Vaccines against SARS-CoV-2: Advantages and Caveats.International journal of molecular sciences · 2023
    Review
12. Local travel behaviour under continuing COVID-19 waves- A proxy for pandemic fatigue?Transportation research interdisciplinary perspectives · 2023
    Article
13. Immunologically effective biomaterials-enhanced vaccines against infection of pathogenic microorganisms.Biosafety and health · 2023
    Review
14. SARS-CoV-2 Spike Protein Mutations in Different Variants: A Comparison Between Vaccinated and Unvaccinated Population in Western Amazonia.Bioinformatics and biology insights · 2023
    Article
15. The role of vaccination route with an adenovirus-vectored vaccine in protection, viral control, and transmission in the SARS-CoV-2/K18-hACE2 mouse infection model.Frontiers in immunology · 2023
    Article
16. Long COVID in the context of social determinants of health.Frontiers in public health · 2023
    Article
17. Effect of an Inhibitor on the ACE2-Receptor-Binding Domain of SARS-CoV-2.Journal of chemical information and modeling · 2022
    Article
18. Reduction in COVID-19 Vaccine Effectiveness against SARS-CoV-2 Variants in Seoul according to Age, Sex, and Symptoms: A Test-Negative Case-Control Study.International journal of environmental research and public health · 2022
    Article
19. Combining intramuscular and intranasal homologous prime-boost with a chimpanzee adenovirus-based COVID-19 vaccine elicits potent humoral and cellular immune responses in mice.Emerging microbes & infections · 2022
    Article
20. Assessment of the post-SARS-CoV-2 vaccination response depending on the epidemiological status, demographic parameters and levels of selected cytokines in medical personnel.Postepy dermatologii i alergologii · 2022
    Article

Corrections and comments

• Comment on
  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.2020

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as